{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T01:24:32Z","timestamp":1784597072312,"version":"3.55.0"},"reference-count":133,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.ctrv.2015.05.001","type":"journal-article","created":{"date-parts":[[2015,5,8]],"date-time":"2015-05-08T07:46:15Z","timestamp":1431071175000},"page":"486-495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["The established and future biomarkers of malignant pleural mesothelioma"],"prefix":"10.1016","volume":"41","author":[{"given":"V.","family":"Panou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Vyberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.M.","family":"Weinreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Meristoudis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.G.","family":"Falkmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.D.","family":"R\u00f8e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2015.05.001_b0005","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/jcp.22724","article-title":"Malignant mesothelioma: facts, myths and hypotheses","volume":"227","author":"Carbone","year":"2012","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0010","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S0140-6736(05)67025-0","article-title":"Malignant mesothelioma","volume":"366","author":"Robinson","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2015.05.001_b0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00420-008-0358-5","article-title":"The relationship between malignant mesothelioma and an asbestos cement plant environmental risk: a spatial case\u2013control study in the city of Bari (Italy)","volume":"82","author":"Musti","year":"2009","journal-title":"Int Arch Occup Environ Health"},{"key":"10.1016\/j.ctrv.2015.05.001_b0020","doi-asserted-by":"crossref","first-page":"647","DOI":"10.5858\/arpa.2012-0214-OA","article-title":"Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group","volume":"137","author":"Husain","year":"2013","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ctrv.2015.05.001_b0025","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/PAS.0b013e31814faacf","article-title":"Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin","volume":"32","author":"Padgett","year":"2008","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0030","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0035","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/j.athoracsur.2007.04.076","article-title":"Outcomes after extrapleural pneumonectomy and intensity-modulated radiation therapy for malignant pleural mesothelioma","volume":"84","author":"Rice","year":"2007","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.ctrv.2015.05.001_b0040","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","article-title":"Pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility","volume":"12","author":"Treasure","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0045","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1136\/thoraxjnl-2013-203846","article-title":"Surgery in the treatment of malignant pleural mesothelioma: recruitment into trials should be the default position","volume":"69","author":"Datta","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ctrv.2015.05.001_b0050","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.lungcan.2013.04.019","article-title":"Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: The outcome of incomplete resections","volume":"81","author":"Bolukbas","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1111\/j.1440-1843.2005.00763.x","article-title":"Prolonged survival after talc poudrage for malignant pleural mesothelioma: case series","volume":"10","author":"Aelony","year":"2005","journal-title":"Respirology"},{"key":"10.1016\/j.ctrv.2015.05.001_b0060","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1515\/CCLM.2011.242","article-title":"Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma","volume":"49","author":"Yamada","year":"2011","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.ctrv.2015.05.001_b0065","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ctrv.2015.05.001_b0070","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000377697","article-title":"Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma","volume":"59","author":"Hjerpe","year":"2015","journal-title":"Acta Cytol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0075","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1097\/00000478-199712000-00003","article-title":"The immunohistochemical diagnostic panel for epithelial mesothelioma: a reevaluation after heat-induced epitope retrieval","volume":"21","author":"Riera","year":"1997","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0080","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1097\/PAS.0b013e31825d5371","article-title":"Utility of a CEA, CD15, calretinin, and CK5\/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice","volume":"36","author":"Mohammad","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0085","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0344-0338(96)80208-1","article-title":"The calcium binding protein calretinin is a selective marker for malignant pleural mesotheliomas of the epithelial type","volume":"192","author":"Gotzos","year":"1996","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ctrv.2015.05.001_b0090","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2559.2005.02331.x","article-title":"Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data","volume":"48","author":"King","year":"2006","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2015.05.001_b0095","unstructured":"Available at: <http:\/\/www.nordicq.org\/Run-33-B12-G2\/Assessment\/assessment-33-CR.htm.>; n.d. [accessed 15.04.15]."},{"key":"10.1016\/j.ctrv.2015.05.001_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2006.08.010","article-title":"What are the current best immunohistochemical markers for the diagnosis of epithelioid mesothelioma? A review and update","volume":"38","author":"Ord\u00f3\u00f1ez","year":"2007","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0105","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2303.2007.00482.x","article-title":"The value of calretinin and cytokeratin 5\/6 as markers for mesothelioma in cell block preparations of serous effusions","volume":"19","author":"Shield","year":"2008","journal-title":"Cytopathology"},{"key":"10.1016\/j.ctrv.2015.05.001_b0110","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/dc.20747","article-title":"Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5\/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions","volume":"36","author":"Pu","year":"2008","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0115","unstructured":"Available at: <http:\/\/www.nordicq.org\/Run-38\/Assessment\/assessment-38-CK-HMW.htm.>; n.d. [accessed 15.04.15]."},{"key":"10.1016\/j.ctrv.2015.05.001_b0120","unstructured":"Available at: <http:\/\/www.nordicq.org\/Run-36-B14H2\/Assessment\/assessment-36-PODOP.htm.>; n.d. [accessed 15.04.15]."},{"key":"10.1016\/j.ctrv.2015.05.001_b0125","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/dc.20556","article-title":"The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement","volume":"34","author":"Saad","year":"2006","journal-title":"Diagn Cytopathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0130","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.prp.2009.06.001","article-title":"Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?","volume":"205","author":"Deniz","year":"2009","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.ctrv.2015.05.001_b0135","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/01.pap.0000213007.48479.94","article-title":"Podoplanin: a novel diagnostic immunohistochemical marker","volume":"13","author":"Ord\u00f3\u00f1ez","year":"2006","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0140","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/modpathol.3800736","article-title":"D2-40 and calretinin \u2013 a tissue microarray analysis of 341 malignant mesotheliomas with emphasis on sarcomatoid differentiation","volume":"20","author":"Hinterberger","year":"2007","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0145","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.humpath.2005.01.019","article-title":"D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma","volume":"36","author":"Ord\u00f3\u00f1ez","year":"2005","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0150","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/PAI.0b013e318187dd26","article-title":"Comparison of different clones (WT49 versus 6F-H2) of WT-1 antibodies for immunohistochemical diagnosis of malignant pleural mesothelioma","volume":"17","author":"Tsuta","year":"2009","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0155","first-page":"344","article-title":"Wilms\u2019 tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma","volume":"146","author":"Amin","year":"1995","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0160","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/gcc.2870120203","article-title":"Expression of the Wilms\u2019 tumor gene WT1 in human malignant mesothelioma cell lines and relationship to platelet-derived growth factor A and insulin-like growth factor 2 expression","volume":"12","author":"Langerak","year":"1995","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0165","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/ajcp\/86.2.227","article-title":"Pleural malignant mesothelioma following Wilms\u2019 tumor","volume":"86","author":"Austin","year":"1986","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1046\/j.1365-2559.2000.00770.x","article-title":"HBME-1, MOC-31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma","volume":"36","author":"Oates","year":"2000","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2015.05.001_b0175","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/(SICI)1096-9896(199701)181:1<67::AID-PATH723>3.0.CO;2-Z","article-title":"WT1 mutation in malignant mesothelioma and WT1 immunoreactivity in relation to p53 and growth factor receptor expression, cell-type transition, and prognosis","volume":"181","author":"Kumar-Singh","year":"1997","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0180","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1440-1827.2007.02193.x","article-title":"Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry","volume":"58","author":"Kushitani","year":"2008","journal-title":"Pathol Int"},{"key":"10.1016\/j.ctrv.2015.05.001_b0185","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1111\/j.1365-2559.2011.04108.x","article-title":"High Wilms\u2019 tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma","volume":"60","author":"Scattone","year":"2012","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2015.05.001_b0190","unstructured":"Available at: <http:\/\/www.nordicq.org\/Run-28\/Assessment\/assessment-28-WT1.htm.>; n.d. [accessed 15.04.15]."},{"key":"10.1016\/j.ctrv.2015.05.001_b0195","unstructured":"Available at: <http:\/\/www.nordiqc.org\/Run-43-B19-H7\/Assessment\/Run43_WT1.pdf>; n.d. [accessed 26.04.15]."},{"key":"10.1016\/j.ctrv.2015.05.001_b0200","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1097\/00000478-200308000-00001","article-title":"The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma","volume":"27","author":"Ord\u00f3\u00f1ez","year":"2003","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0205","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/j.humpath.2009.02.013","article-title":"Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions","volume":"40","author":"Yuan","year":"2009","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0210","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1309\/AJCPM2Z4NGIIPBGE","article-title":"CD90 is a diagnostic marker to differentiate between malignant pleural mesothelioma and lung carcinoma with immunohistochemistry","volume":"140","author":"Kawamura","year":"2013","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0215","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.lungcan.2011.07.009","article-title":"Proteomic surfaceome analysis of mesothelioma","volume":"75","author":"Ziegler","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0220","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/modpathol.2012.200","article-title":"Value of PAX8, PAX2, claudin-4, and h-caldesmon immunostaining in distinguishing peritoneal epithelioid mesotheliomas from serous carcinomas","volume":"26","author":"Ord\u00f3\u00f1ez","year":"2013","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0225","unstructured":"Available at: <http:\/\/www.nordicq.org\/Run-37-B15-H3\/Assessment\/assessment-37-CEA.htm>; n.d. [accessed 15.04.15]."},{"key":"10.1016\/j.ctrv.2015.05.001_b0230","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1164\/rccm.200511-1789OC","article-title":"Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma","volume":"173","author":"Scherpereel","year":"2006","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ctrv.2015.05.001_b0235","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.lungcan.2007.12.025","article-title":"Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case\u2013control study","volume":"61","author":"Roe","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0240","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/S0140-6736(03)14794-0","article-title":"Mesothelin-family proteins and diagnosis of mesothelioma","volume":"362","author":"Robinson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2015.05.001_b0245","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1158\/1078-0432.CCR-07-0629","article-title":"Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer","volume":"13","author":"Cristaudo","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0250","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/1055-9965.EPI-08-0422","article-title":"Serum levels of soluble mesothelin-related peptides in malignant and nonmalignant asbestos-related pleural disease: relation with past asbestos exposure","volume":"18","author":"Rodr\u00edguez Portal","year":"2009","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ctrv.2015.05.001_b0255","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1378\/chest.11-0129","article-title":"The effect of clinical covariates on the diagnostic and prognostic value of soluble mesothelin and megakaryocyte potentiating factor","volume":"141","author":"Hollevoet","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.ctrv.2015.05.001_b0260","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.athoracsur.2007.07.042","article-title":"Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions","volume":"85","author":"Pass","year":"2008","journal-title":"Ann Thorac Surg"},{"issue":"9","key":"10.1016\/j.ctrv.2015.05.001_b0265","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1097\/JTO.0b013e3181e392d7","article-title":"Sensitivity of urinary mesothelin in patients with malignant mesothelioma","volume":"5","author":"Creaney","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctrv.2015.05.001_b0270","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1097\/JTO.0b013e318187491c","article-title":"Diagnostic and prognostic value of soluble mesothelin-related proteins in patients with malignant pleural mesothelioma in comparison with benign asbestosis and lung cancer","volume":"3","author":"Schneider","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0275","first-page":"224","article-title":"Soluble mesothelin-related protein in malignant pleural mesothelioma","volume":"20","author":"Azim","year":"2008","journal-title":"J Egypt Natl Canc Inst"},{"key":"10.1016\/j.ctrv.2015.05.001_b0280","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"Beyer","year":"2007","journal-title":"Clin Chem"},{"key":"10.1016\/j.ctrv.2015.05.001_b0285","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1164\/rccm.200907-1020OC","article-title":"Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma","volume":"181","author":"Hollevoet","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ctrv.2015.05.001_b0290","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1136\/thx.2006.068114","article-title":"Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma","volume":"62","author":"Creaney","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.ctrv.2015.05.001_b0295","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1158\/1078-0432.CCR-07-1613","article-title":"Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC\/mesothelin increases its potential as a useful serum tumor marker for mesothelioma","volume":"14","author":"Shiomi","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0300","first-page":"3933","article-title":"ERC\/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma","volume":"28","author":"Tajima","year":"2008","journal-title":"Anticancer Res"},{"issue":"Suppl. 1","key":"10.1016\/j.ctrv.2015.05.001_b0305","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1016\/j.lungcan.2005.03.020","article-title":"Soluble mesothelin-related protein \u2013 a blood test for mesothelioma","volume":"49","author":"Robinson","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0310","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1158\/1078-0432.CCR-06-2144","article-title":"Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment","volume":"13","author":"Grigoriu","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0315","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1158\/1078-0432.CCR-10-1929","article-title":"Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden","volume":"17","author":"Creaney","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0320","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1164\/rccm.200811-1729OC","article-title":"Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions","volume":"180","author":"Davies","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ctrv.2015.05.001_b0325","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1056\/NEJMoa051185","article-title":"Asbestos exposure, pleural mesothelioma, and serum osteopontin levels","volume":"353","author":"Pass","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.05.001_b0330","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/JTO.0b013e318180477b","article-title":"Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma","volume":"3","author":"Creaney","year":"2008","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0335","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","article-title":"Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma","volume":"6","author":"Cristaudo","year":"2011","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0340","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/modpathol.3800259","article-title":"Utility of D2-40, a novel mesothelial marker, in the diagnosis of malignant mesothelioma","volume":"18","author":"Chu","year":"2005","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0345","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"Pass","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2015.05.001_b0350","first-page":"1","article-title":"Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma","author":"Creaney","year":"2014","journal-title":"Thorax"},{"key":"10.1016\/j.ctrv.2015.05.001_b0355","doi-asserted-by":"crossref","DOI":"10.1016\/S0021-9258(18)73363-2","article-title":"Hyaluronic acid in the pleural fluid associated with a malignant tumor involving the pleura and peritoneum","author":"Meyer","year":"1940","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2015.05.001_b0360","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/1097-0142(20010901)92:5<1224::AID-CNCR1441>3.0.CO;2-U","article-title":"Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma","volume":"92","author":"Thyl\u00e9n","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0365","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/clinchem\/40.5.777","article-title":"Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content","volume":"40","author":"Nurminen","year":"1994","journal-title":"Clin Chem"},{"key":"10.1016\/j.ctrv.2015.05.001_b0370","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s00428-007-0375-x","article-title":"Cytological diagnosis of malignant mesothelioma \u2013 improvement by additional analysis of hyaluronic acid in pleural effusions","volume":"450","author":"Welker","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ctrv.2015.05.001_b0375","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.lungcan.2013.09.016","article-title":"Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma","volume":"82","author":"Creaney","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0380","doi-asserted-by":"crossref","first-page":"R84","DOI":"10.1186\/bcr3199","article-title":"CD44 enhances invasion of basal-like breast cancer cells by up-regulating serine protease and collagen-degrading enzymatic expression and activity","volume":"14","author":"Hill","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0385","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.ajpath.2011.06.005","article-title":"Prostate cancer increases hyaluronan in surrounding nonmalignant stroma, and this response is associated with tumor growth and an unfavorable outcome","volume":"179","author":"Granfors","year":"2011","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0390","doi-asserted-by":"crossref","first-page":"19821","DOI":"10.1074\/jbc.M110.104273","article-title":"Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor","volume":"285","author":"Ghatak","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2015.05.001_b0395","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5009\/gnl.2011.5.4.397","article-title":"The role of CD44 in the pathogenesis, diagnosis, and therapy of gastric cancer","volume":"5","author":"Li","year":"2011","journal-title":"Gut Liver"},{"key":"10.1016\/j.ctrv.2015.05.001_b0400","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.clinbiochem.2009.03.007","article-title":"Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma","volume":"42","author":"Grigoriu","year":"2009","journal-title":"Clin Biochem"},{"key":"10.1016\/j.ctrv.2015.05.001_b0405","doi-asserted-by":"crossref","first-page":"e72030","DOI":"10.1371\/journal.pone.0072030","article-title":"Hyaluronan and N-ERC\/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma","volume":"8","author":"Mundt","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2015.05.001_b0410","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1158\/0008-5472.CAN-08-4073","article-title":"Oral cancer diagnosis by mechanical phenotyping","volume":"69","author":"Remmerbach","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0415","doi-asserted-by":"crossref","first-page":"212ra163","DOI":"10.1126\/scitranslmed.3006559","article-title":"Quantitative diagnosis of malignant pleural effusions by single-cell mechanophenotyping","volume":"5","author":"Tse","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2015.05.001_b0420","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/1559-0275-10-16","article-title":"Identification of a seven glycopeptide signature for malignant pleural mesothelioma in human serum by selected reaction monitoring","volume":"10","author":"Cerciello","year":"2013","journal-title":"Clin Proteomics"},{"key":"10.1016\/j.ctrv.2015.05.001_b0425","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2009.05.004","article-title":"Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions","volume":"68","author":"Flores-Staino","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0430","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.7314\/APJCP.2012.13.9.4745","article-title":"Diagnostic value of fluorescence in situ hybridization assay in malignant mesothelioma: a meta-analysis","volume":"13","author":"Wan","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.ctrv.2015.05.001_b0435","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/gcc.20669","article-title":"CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma \u2014 a miRNA microarray analysis","volume":"48","author":"Guled","year":"2009","journal-title":"Genes Chromosom Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0440","doi-asserted-by":"crossref","first-page":"e58586","DOI":"10.1371\/journal.pone.0058586","article-title":"Identification of human microRNA-like sequences embedded within the protein-encoding genes of the human immunodeficiency virus","volume":"8","author":"Holland","year":"2013","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ctrv.2015.05.001_b0445","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1097\/JTO.0b013e31820db125","article-title":"MicroRNAs dysregulation in human malignant pleural mesothelioma","volume":"6","author":"Balatti","year":"2011","journal-title":"J Thorac Oncol."},{"key":"10.1016\/j.ctrv.2015.05.001_b0450","doi-asserted-by":"crossref","first-page":"5003","DOI":"10.1073\/pnas.1019055108","article-title":"Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma","volume":"108","author":"Arroyo","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2015.05.001_b0455","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"Kirschner","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0460","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1165\/rcmb.2009-0060OC","article-title":"MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications","volume":"42","author":"Busacca","year":"2010","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0465","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1002\/ijc.25285","article-title":"Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma","volume":"127","author":"Gee","year":"2010","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0470","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1158\/0008-5472.CAN-09-3993","article-title":"Hsa-miR-29c* is linked to the prognosis of malignant pleural mesothelioma","volume":"70","author":"Pass","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0475","doi-asserted-by":"crossref","first-page":"e18232","DOI":"10.1371\/journal.pone.0018232","article-title":"Association of MiR-126 with soluble mesothelin-related peptides, a marker for malignant mesothelioma","volume":"6","author":"Santarelli","year":"2011","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ctrv.2015.05.001_b0480","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.molonc.2014.11.007","article-title":"MiR-score: a novel 6-microRNA signature that predicts survival outcomes in patients with malignant pleural mesothelioma","volume":"9","author":"Kirschner","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ctrv.2015.05.001_b0485","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.lungcan.2009.03.016","article-title":"Malignant pleural mesothelioma: genome-wide expression patterns reflecting general resistance mechanisms and a proposal of novel targets","volume":"67","author":"R\u00f8e","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0490","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0014-5793(00)01913-X","article-title":"Differential gene expression in mesothelioma","volume":"480","author":"Rihn","year":"2000","journal-title":"FEBS Lett"},{"key":"10.1016\/j.ctrv.2015.05.001_b0495","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2164-8-62","article-title":"Gene expression profiles in asbestos-exposed epithelial and mesothelial lung cell lines","volume":"8","author":"Nymark","year":"2007","journal-title":"BMC Genomics"},{"key":"10.1016\/j.ctrv.2015.05.001_b0500","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.biochi.2003.11.008","article-title":"Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells","volume":"86","author":"Mohr","year":"2004","journal-title":"Biochimie"},{"key":"10.1016\/j.ctrv.2015.05.001_b0505","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/carcin\/bgh276","article-title":"L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray","volume":"26","author":"Kettunen","year":"2005","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ctrv.2015.05.001_b0510","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/path.2120","article-title":"Inhibitor of apoptosis proteins are regulated by tumour necrosis factor-\u03b1 in malignant pleural mesothelioma","volume":"211","author":"Gordon","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0515","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-06-1101","article-title":"In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion","volume":"12","author":"Szlosarek","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0520","doi-asserted-by":"crossref","first-page":"e6554","DOI":"10.1371\/journal.pone.0006554","article-title":"Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype","volume":"4","author":"R\u00f8e","year":"2009","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2015.05.001_b0525","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/1078-0432.CCR-0607-3","article-title":"Gene expression profiles predict survival and progression of pleural mesothelioma","volume":"10","author":"Pass","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0530","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cancergencyto.2006.05.002","article-title":"High-resolution analysis of 9p loss in human cancer cells using single nucleotide polymorphism-based mapping arrays","volume":"170","author":"Pei","year":"2006","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.ctrv.2015.05.001_b0535","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1349-7006.2006.00386.x","article-title":"Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32","volume":"98","author":"Taniguchi","year":"2007","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2015.05.001_b0540","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12199-007-0015-8","article-title":"Molecular biology of malignant mesothelioma","volume":"13","author":"Sekido","year":"2008","journal-title":"Environ Health Prev Med"},{"key":"10.1016\/j.ctrv.2015.05.001_b0545","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s10147-011-0369-1","article-title":"Pathological and molecular biological approaches to early mesothelioma","volume":"17","author":"Tsujimura","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0550","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1016\/S0002-9440(10)62492-3","article-title":"Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling","volume":"166","author":"Gordon","year":"2005","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0555","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.bbadis.2003.10.007","article-title":"Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray","volume":"1688","author":"Mohr","year":"2004","journal-title":"Biochim Biophys Acta \u2013 Mol Basis Dis"},{"key":"10.1016\/j.ctrv.2015.05.001_b0560","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1158\/0008-5472.CAN-05-3907","article-title":"Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16\/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction","volume":"66","author":"L\u00f3pez-R\u00edos","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0565","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1349-7006.2006.00184.x","article-title":"Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients","volume":"97","author":"Usami","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2015.05.001_b0570","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1158\/1078-0432.CCR-13-2429","article-title":"Molecular classification of malignant pleural mesothelioma: identification of a poor prognosis subgroup linked to the epithelial-to-mesenchymal transition","volume":"20","author":"De Reynie","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0575","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jnci\/djp061","article-title":"Four-gene expression ratio test for survival in patients undergoing surgery for mesothelioma","volume":"101","author":"Gordon","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2015.05.001_b0580","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1093\/jnci\/95.8.598","article-title":"Using gene expression ratios to predict outcome among patients with mesothelioma","volume":"95","author":"Gordon","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2015.05.001_b0585","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-10-0806","article-title":"Fine-needle aspiration biopsies for gene expression ratio-based diagnostic and prognostic tests in malignant pleural mesothelioma","volume":"17","author":"De Rienzo","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0590","doi-asserted-by":"crossref","first-page":"e26332","DOI":"10.1371\/journal.pone.0026332","article-title":"From SOMAmer-based biomarker discovery to diagnostic and clinical applications: a SOMAmer-based, streamlined multiplex proteomic assay","volume":"6","author":"Kraemer","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2015.05.001_b0595","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1002\/pmic.200800284","article-title":"Proteomic differential display analysis identified upregulated astrocytic phosphoprotein PEA-15 in human malignant pleural mesothelioma cell lines","volume":"9","author":"Kuramitsu","year":"2009","journal-title":"Proteomics"},{"key":"10.1016\/j.ctrv.2015.05.001_b0600","doi-asserted-by":"crossref","first-page":"e46091","DOI":"10.1371\/journal.pone.0046091","article-title":"Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool","volume":"7","author":"Ostroff","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2015.05.001_b0605","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.molcel.2011.08.018","article-title":"Molecular mechanisms of long noncoding RNAs","volume":"43","author":"Wang","year":"2011","journal-title":"Mol Cell"},{"key":"10.1016\/j.ctrv.2015.05.001_b0610","doi-asserted-by":"crossref","first-page":"703","DOI":"10.4161\/rna.20481","article-title":"The hallmarks of cancer: a long non-coding RNA point of view","volume":"9","author":"Gutschner","year":"2012","journal-title":"RNA Biol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0615","doi-asserted-by":"crossref","first-page":"e70940","DOI":"10.1371\/journal.pone.0070940","article-title":"Long non coding RNAs (lncRNAs) are dysregulated in malignant pleural mesothelioma (MPM)","volume":"8","author":"Wright","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ctrv.2015.05.001_b0620","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrc3459","article-title":"BAP1 and cancer","volume":"13","author":"Carbone","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2015.05.001_b0625","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2015.05.001_b0630","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/ng.855","article-title":"The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma","volume":"43","author":"Bott","year":"2011","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2015.05.001_b0635","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2012.02223.x","article-title":"Frequent inactivation of the BAP1 gene in epithelioid-type malignant mesothelioma","volume":"103","author":"Yoshikawa","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2015.05.001_b0640","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1200\/JCO.2009.25.9275","article-title":"Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy","volume":"28","author":"Righi","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0645","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-10-2873","article-title":"Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed\/carboplatin","volume":"17","author":"Zucali","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2015.05.001_b0650","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/JTO.0b013e318287c224","article-title":"Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma","volume":"8","author":"Mairinger","year":"2013","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0655","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1097\/JTO.0b013e318260deaa","article-title":"Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma","volume":"7","author":"Christoph","year":"2012","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0660","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00280-012-1965-0","article-title":"A biomarker profile for predicting efficacy of cisplatin\u2013vinorelbine therapy in malignant pleural mesothelioma","volume":"70","author":"Zimling","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2015.05.001_b0665","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/path.3979","article-title":"BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma","volume":"227","author":"Busacca","year":"2012","journal-title":"J Pathol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215000961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737215000961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,7]],"date-time":"2022-05-07T14:28:47Z","timestamp":1651933727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737215000961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":133,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,6]]}},"alternative-id":["S0305737215000961"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.05.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The established and future biomarkers of malignant pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2015.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}